Navigation Links
Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

headache (27%), vomiting (25%), peripheral edema (23%), rash (22%), diarrhea (22%), myalgia (19%), cough (19%), asthenia (18%), pruritus (17%), back pain (17%), anorexia (15%), arthralgia (14%) and upper respiratory tract infection (13%).

The percentage of patients reporting serious adverse events (SAEs) was higher for ONTAK than for placebo. Drug-related SAEs in ONTAK-treated patients were capillary leak syndrome (4%), dehydration (4%), hypotension (3%), fever (3%), hypoalbuminemia (2%), skin disorder (2%), chest pain (2%), vascular fragility (2%), fatigue (2%), hypersensitivity (2%), myocardial ischemia (1%), urinary tract infection (1%), blood pressure decreased (1%), joint stiffness (1%), myalgia (1%), carpel tunnel syndrome (1%), loss of consciousness (1%), respiratory distress (1%), dermatitis exfoliative (1%), erythema (1%), and rash generalized (1%). The frequency of SAEs decreased after the first two cycles of treatment. The percentage of patients overall who discontinued the study due to an adverse event was higher in the ONTAK group (20.0%) compared with the placebo group (9.1%).

"We are pleased that research continues with ONTAK in the treatment of patients with CTCL," said Judy Jones, Executive Director of the Cutaneous Lymphoma Foundation. "This study reflects Eisai's ongoing commitment to satisfying unmet medical needs in oncology, particularly in CTCL, a form of cancer for which there is no cure."

About ONTAK(R) (denileukin diftitox)

ONTAK is a genetically engineered fusion toxin protein consisting of the amino acid sequences for the enzymatically-active portion of diphtheria toxin fused to the sequence of human interleukin-2, resulting in a molecule that is cytotoxic for cells bearing the target IL-2 receptor expressed on malignant cells.

ONTAK is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 recepto
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
2. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
3. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
4. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
5. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
6. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
7. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
8. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
11. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
Post Your Comments:
(Date:10/1/2014)... Oct. 1, 2014 Ardelyx, Inc. ... biopharmaceutical company focused on cardio-renal, gastrointestinal and ... its 371 patient Phase 2b clinical trial ... bowel syndrome (IBS-C).  Results from this study ... in IBS-C symptoms for tenapanor-treated patients compared ...
(Date:10/1/2014)... Suisse, October 1, 2014 ... dans le domaine de l,analyse des données issues ... une solution de diagnostic in vitro (IVD) du ... complète de la mucoviscidose dans un seul essai ... caractériser tous les types de variantes par l,intermédiaire ...
(Date:9/30/2014)... health and safety of Canadians is our government,s highest priority.  Our ... at its disposal to help ensure that the drugs Canadians need ... end, Health Canada has taken decisive ... of all drug products from three plants in ... Pharmachem India Pvt Ltd , Apotex Research Private Limited ...
Breaking Medicine Technology:Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new ... retired couples. , Senior citizens can purchase a ... their loved ones. A joint policy is cheaper, but ... away. , Life insurance can be used to ... even be purchased online, as the application process is ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post ... for smokers. , Smoking will always have a negative ... the best method to find affordable coverage. Insurance brokerage ... coverage. , Whole life insurance premiums will be ... the coverage is permanent, the initial rates are ...
(Date:10/1/2014)... October 01, 2014 T.E.N., ... and relationship-marketing firm, announced today the nominees ... and Project of the Year Awards for ... representing organizations in financial services, commercial, health ... technology endeavors that address key issues in ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests ... and depression might also be hard-wired to gain weight ... heart disease. , An estimated 13 percent of people, ... susceptibility, and knowing this could help them reduce heart ... exercise and stress management. , "Genetic susceptibility, psychosocial stress ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Innovations announces ... scheduled to broadcast on Monday, October 20, 2014 at ... episode, Innovations will go behind the scenes to learn ... This segment will explore the practical help and information ... which teaches the warning signs of abuse, how to ...
Breaking Medicine News(10 mins):Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... Actress Sanaa Lathan Celebrates Inspirational Stories of how ... ENGLEWOOD CLIFFS, N.J., May 28 Skin is,amazing: it ... is a,symbol of pride, for others it,s a canvas to ... heritage to be honored. Skin means something different,to almost everyone ...
... SYK ) announced today that it will participate ... - 9:00 a.m. Eastern Time Seventh Annual Needham ... New York, New York, June 12, 2008 ... Annual Global Healthcare Conference Dana Point, California ...
... areas around the mouth and neck the sights in ... inevitable. They result from a structural breakdown inside the skin ... of new, youthful collagen, University of Michigan scientists say. ... and possible renewal, based on more than a decade of ...
... WASHINGTON, May 28 Legendary music producer,and ... for survivors,of the catastrophic earthquake that struck ... Myanmar. Jones recently recorded several public services,announcements ... now available to the,media ( http://www.redcross.org/QuincyJonesPSA )., ...
... protein MAEBL is critical for completing the life cycle ... transmit the potentially deadly infection to humans, a University ... ultimately help provide a way to better control malaria ... mosquito. , Researchers with the USF Global Health Infectious ...
... in the May 28, 2008 edition of The Journal ... action of certain brain cells altered by chronic alcohol ... the central amygdala, which plays an important role in ... alcohol drinking. In the study, alcohol-dependent rodents receiving gabapentin ...
Cached Medicine News:Health News:Vaseline(R) Cocoa Butter Campaign Uncovers Skin's Ability to Speak Volumes 2Health News:Vaseline(R) Cocoa Butter Campaign Uncovers Skin's Ability to Speak Volumes 3Health News:Vaseline(R) Cocoa Butter Campaign Uncovers Skin's Ability to Speak Volumes 4Health News:Stryker to Present at Investor Conferences 2Health News:Why some treatments rescue aging skin 2Health News:Why some treatments rescue aging skin 3Health News:Quincy Jones Lends Time and Talent to Support Red Cross Relief Efforts In China and Myanmar 2Health News:Protein plays key role in transmitting deadly malaria parasite 2Health News:Scripps Research scientists find seizure drug reverses cellular effects 2
... BrainSUITE iMRI is a neurosurgical OR ... and diagnostic tools, including iMRI, necessary ... BrainSUITE iMRI, neurosurgical treatments are performed ... and designed for MR compatibility and ...
... magnetic stimulator to offer the practical advantages ... designed to provide the simplest operation possible ... the same time, it may also help ... operations without moving away from your patient). ...
... The X-SIZER System ... catheter system for thrombus ... arteries and saphenous vein ... featuring,stainless steel cutter and,continuous ...
... Power, Deeper Lesions ,Designed for the ... Freezor MAX is a powerful ablation-only catheter. ... ablation tip was designed to provide maximum ... same cryoconsole as the other cryocatheters, but ...
Medicine Products: